Global Lyme Disease Preventive Vaccine Shot Market Size To Exceed USD 208.89 Million by 2033: Market Insight Report

Global Lyme Disease Preventive Vaccine Shot Market Size To Exceed USD 208.89 Million by 2033

According to a research report published by Spherical Insights & Consulting, The Global Lyme Disease Preventive Vaccine Shot Market Size is Expected to Grow from USD 34.89 Million in 2023 to USD 208.89 Million by 2033, at a CAGR of 19.60% during the forecast period 2023-2033.          

Browse 210 market data Tables and 45 Figures spread through 190 Pages and in-depth TOC on the Global Lyme Disease Preventive Vaccine Shot Market Size, Share, and COVID-19 Impact Analysis, By Type (Lyme PeRP and Vla- 15), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.

The Lyme disease preventive vaccine shot market describes the vaccine development, manufacturing, marketing, and selling industry, specifically aimed at producing vaccines against Lyme disease caused by a bacterial infection transmitted from an infected black-legged tick bite (Ixodes scapularis). It is an array of different pharmaceutical businesses, biotech industries, health practitioners, and research facilities producing innovative formulations for vaccine creation for treating Lyme disease. Furthermore, the world Lyme disease preventive vaccine shot market is fueled by growing Lyme disease incidence, greater awareness, advancements in vaccine technology, and government policies. Prominent companies such as Pfizer and Valneva drive expansion through clinical trials. Favorable regulatory environments and R&D investments are also expanding the market, particularly in high-risk areas such as North America and Europe. However, Key restraining factors include high R&D costs, stringent regulatory approvals, limited awareness, vaccine hesitancy, potential side effects, competition from alternative treatments, and the historical failure of past Lyme disease vaccines.

The Vla- 15 segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

On the basis of the type, the global Lyme disease preventive vaccine shot market is divided into Lyme PeRP and Vla-15. Among these, the Vla- 15 segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The segmental growth is attributed to its advanced clinical development by Pfizer and Valneva, strong efficacy against multiple Borrelia strains, and growing demand for Lyme disease prevention. Favorable regulatory progress, increased funding, and rising Lyme disease cases further drive its anticipated significant CAGR during the forecast period.

North America is projected to hold the largest share of the global Lyme disease preventive vaccine shot market over the forecast period.

North America is projected to hold the largest share of the global Lyme disease preventive vaccine shot market over the forecast period. The regional growth is attributed to high Lyme disease incidence, increasing awareness, advanced healthcare infrastructure, and strong government initiatives. The presence of key players like Pfizer, ongoing clinical trials, and rising demand for preventive solutions further contribute to the region’s significant market share and growth potential.

Asia Pacific is expected to grow at the fastest CAGR growth of the global Lyme disease preventive vaccine shot market during the forecast period. The regional growth is attributed to rising healthcare awareness, improving medical infrastructure, and increasing cases of Lyme disease in certain regions. Expanding vaccine research, government initiatives, and growing investments from pharmaceutical companies in emerging markets like China and India further drive rapid market growth during the forecast period.

Company Profiling

Major vendors in the global Lyme disease preventive vaccine shot market are Valneva SE, Pfizer, Mass Biologics, Shire, Baxter International, Inc., and others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In September 2024, the Lyme disease vaccine candidate developed by Pfizer and Valneva successfully finished a Phase 2 clinical trial, proving to be safe and generating an immune response.  The businesses anticipate starting a Phase 3 trial shortly.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global Lyme disease preventive vaccine shot market based on the below-mentioned segments: 

Global Lyme Disease Preventive Vaccine Shot Market, By Type

• Lyme PeRP
• Vla- 15

Global Lyme Disease Preventive Vaccine Shot Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa